Executive Profiles

Natalie Bickford, chief people officer at Sanofi, reveals how she approaches the employee experience, which ultimately influences employee retention, and discusses the importance of a corporate DE&I strategy in those efforts.

Kimberly Moran, head of rare diseases in the US for UCB, started off working in medicine but quickly learned the importance of the business side of industry—and its role in helping improve the diagnosis and access paths for underserved patient segments.

Christi Shaw, CEO of Kite, is working hard to bring cell therapy to the masses, fueled by her family’s personal experiences with cancer.

Bristol Myers Squibb commercial head Chris Boerner believes a straightforward formula is the best formula in advancing innovation and developing talent in today’s complex healthcare climate—an approach he roots in authenticity and “not over engineering,” whether tackling business or culture.

Pharm Exec catches up with longtime Merck international business leader Kevin Ali to find out how Organon, the ambitious Merck spinoff he formed just over a year ago, has fared so far in delivering on its mission of creating a global leader and difference-maker in women’s health.

Marie-France Tschudin, president, innovative medicines international, and chief commercial officer at Novartis, taps into life lessons to help bring therapies to people in novel ways­.

Dealing with discrimination and bias throughout her career, Otsuka Pharmaceutical’s Christine Sakdalan has forged a strong leadership path built around a two-pronged mission—finding true meaning in the patient journey through market research and data analytics, and mentoring and supporting the development of today’s aspiring professionals.

Tremeau CEO Bradford Sippy strikes a new chord with revival of old blockbuster drug—modifying it as a unique treatment for orphan hemophilia condition.

The stages of a career well-spent in advancing healthcare innovation.

Amid pandemic, leader helps build ‘commercial startup’ from the ground up.

Using edutainment to capture audiences and break down complex medical information.

An entrepreneurial quest to transform oncology treatment.

‘Whole self’ approach to life and leadership keys passion for helping patients.

Motivated by forging new—and needed—pathways in drug development.

A storied climb from chemist, to Middle East sales rep, to master of product launch.

Fast riser in biotech strategy execution seizes on opportunities in immunotherapy.

Physician-scientist turned Big Pharma medical chief sees fruits of labor.

Tenacious drive to reach patients characterizes career.

How an early personal realization in healthcare focus paved path for greater impact.

Saving and transforming as many patients’ lives as possible has been the driving force behind Beth Seidenberg’s audacious career, where she has excelled as a doctor, researcher, and venture capitalist.

After helping lead Novo Nordisk on a transformational journey from a troubled 2016 to double-digit growth in 2021, Doug Langa, Executive Vice President, Head of North America Operations and President of Novo Nordisk, Inc., is calling on his experience of taking the less conventional and sometimes unexpected routes to success to lead Novo Nordisk into new territory.

Illinois BIO‘s (iBIO) new chairperson, Horizon Therapeutic‘s Marilyn Vetter, outlines the work she plans to do to expand the state’s existing life sciences ecosystem.

Ted Schroeder, CEO of Nabriva Therapeutics, is passionate in his forward-thinking approach to finding the next generation of anti-infectives, as resistance to least-expensive, tried-and-true therapies continues to grow.

Biohaven CEO Vlad Coric talks to Pharm Exec about NURTEC ODT’s swift and seismic impact on the migraine market.

Pharm Exec speaks to George Hampton, CEO of Currax, one of the only pharma companies addressing obesity and smoking.

Masahide Goto outlines the world of the Astellas Institute for Regenerative Medicine (AIRM), which serves as the company’s global hub for regenerative medicine and cell therapy research and manufacturing in ophthalmology and other therapeutic areas that have few or no available treatment options.

Ariel Katz, CEO and co-founder of H1, talks about how to find the right KOL for the right audience at the right time.

As emerging technologies are identified, C-suites need to determine how they might be pragmatically deployed as solutions to address their pain points, says IBM‘s Dr. Bernard S. Meyerson.

Myrtle Potter is no stranger to overcoming adversity. As CEO of Sumitovant Biopharma, she has used her entrepreneurship, determination, and inclusive attitude to help her persevere and achieve her highest goals while overseeing five companies—Myovant, Urovant, Enzyvant, Altavant, and Spirovant.

After two decades at the forefront of hematology and oncology drug development, AbbVie’s vice president and global head of oncology clinical development, Mohamed Zaki, MD, PhD, is more hopeful than ever about recent advances in the space.